Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy.

[1]  Jean-David Fumet,et al.  Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells , 2022, Cancer Research.

[2]  Tae Kon Kim,et al.  Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities , 2022, Nature Reviews Drug Discovery.

[3]  Xiaoting Zhang,et al.  METTL3 inhibits anti-tumor immunity by targeting m6A-BHLHE41-CXCL1/CXCR2 axis to promote colorectal cancer. , 2022, Gastroenterology.

[4]  M. Mandalà,et al.  Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. , 2022, Seminars in cancer biology.

[5]  Carlos L. Arteaga,et al.  Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer. , 2022, Cancer immunology research.

[6]  Lieping Chen,et al.  Resistance Mechanisms to Anti-PD Cancer Immunotherapy. , 2022, Annual review of immunology.

[7]  G. Freeman,et al.  USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy , 2022, Nature Communications.

[8]  Kai Yuan,et al.  m6A Regulator-Mediated Methylation Modification Patterns and Characterisation of Tumour Microenvironment Infiltration in Non-Small Cell Lung Cancer , 2022, Journal of inflammation research.

[9]  Xiang Xu,et al.  METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer , 2022, Molecular cancer.

[10]  Yang Li,et al.  JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA. , 2022, Cancer research.

[11]  Yuan Lin,et al.  M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway , 2021, Cell Death & Differentiation.

[12]  D. Gibbons,et al.  Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. , 2021, Cold Spring Harbor perspectives in medicine.

[13]  C. Boshoff,et al.  Toward personalized treatment approaches for non-small-cell lung cancer , 2021, Nature Medicine.

[14]  Hong-Yang Wang,et al.  M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma , 2021, Cancer Research.

[15]  Shuyuan Liu,et al.  METTL3-mediated m6A modification of Bcl-2 mRNA promotes non-small cell lung cancer progression , 2021, Oncology reports.

[16]  Z. Nwosu,et al.  Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB–Mediated Production of CXCL1 , 2021, Cancer Research.

[17]  Andrew J. Bannister,et al.  Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia , 2021, Nature.

[18]  N. Perrimon,et al.  mTORC1 promotes cell growth via m6A-dependent mRNA degradation. , 2021, Molecular cell.

[19]  A. Luster,et al.  Chemokines and the immune response to cancer. , 2021, Immunity.

[20]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[21]  Chuan He,et al.  m6A RNA methylation: from mechanisms to therapeutic potential , 2021, The EMBO journal.

[22]  Yixuan Hou,et al.  A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability , 2021, Oncogene.

[23]  Jian Wang,et al.  Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme , 2021, Science Advances.

[24]  Bo Zhong,et al.  CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer , 2020, Nature Communications.

[25]  T. Rana,et al.  m6A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy , 2020, The EMBO journal.

[26]  G. Coukos,et al.  Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. , 2020, The Lancet. Oncology.

[27]  Yangqiu Li,et al.  Roles of METTL3 in cancer: mechanisms and therapeutic targeting , 2020, Journal of Hematology & Oncology.

[28]  Samie R. Jaffrey,et al.  A Unified Model for the Function of YTHDF Proteins in Regulating m6A-Modified mRNA , 2020, Cell.

[29]  Xiaole Shirley Liu,et al.  TIMER2.0 for analysis of tumor-infiltrating immune cells , 2020, Nucleic Acids Res..

[30]  Jianjun Chen,et al.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. , 2020, Cancer cell.

[31]  A. Gentles,et al.  MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity , 2020, eLife.

[32]  P. Hegde,et al.  Top 10 Challenges in Cancer Immunotherapy. , 2020, Immunity.

[33]  G. Demetri,et al.  Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma , 2019, Journal of Immunotherapy for Cancer.

[34]  A. O’Garra,et al.  Biology and therapeutic potential of interleukin-10 , 2019, The Journal of experimental medicine.

[35]  S. Jaffrey,et al.  Reading, writing and erasing mRNA methylation , 2019, Nature Reviews Molecular Cell Biology.

[36]  K. Dou,et al.  Notch signaling via Wnt regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma. , 2019, Cancer research.

[37]  Chuan He,et al.  Regulation of Gene Expression by N6-methyladenosine in Cancer. , 2019, Trends in cell biology.

[38]  W. Ouyang,et al.  IL‐10 Family Cytokines IL‐10 and IL‐22: from Basic Science to Clinical Translation , 2019, Immunity.

[39]  Lei Ding,et al.  Stage-specific requirement for Mettl3-dependent m6A mRNA methylation during haematopoietic stem cell differentiation , 2019, Nature Cell Biology.

[40]  J. Galon,et al.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.

[41]  J. Hanna,et al.  m6A modification controls the innate immune response to infection by targeting type I interferons , 2018, Nature Immunology.

[42]  I. Mohr,et al.  RNA m6 A modification enzymes shape innate responses to DNA by regulating interferon β , 2018, Genes & development.

[43]  Kwok-Kin Wong,et al.  mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis , 2018, Nature.

[44]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[45]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[46]  G. Evan,et al.  Myc Cooperates with Ras by Programming Inflammation and Immune Suppression , 2017, Cell.

[47]  Francine E. Garrett-Bakelman,et al.  The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal and leukemia cells , 2017, Nature Medicine.

[48]  L. Heasley,et al.  The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade , 2017, Cancer Immunology Research.

[49]  Lieping Chen,et al.  Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy. , 2016, JAMA oncology.

[50]  R. Herbst,et al.  Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer , 2016, Clinical Cancer Research.

[51]  R. Gregory,et al.  The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. , 2016, Molecular cell.

[52]  L. Chin,et al.  Targeting YAP-dependent MDSC infiltration impairs tumor progression , 2015, Journal of Immunotherapy for Cancer.

[53]  Antoni Ribas,et al.  Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.

[54]  P. Farnham,et al.  c-Myc target gene specificity is determined by a post-DNAbinding mechanism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  John D Lambris,et al.  Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. , 2018, Cancer research.

[56]  R. Herbst,et al.  Programmed death ligand-1 expression in non-small cell lung cancer , 2014, Laboratory Investigation.